Skip to Main Content

Paper Details

OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL.
Clin Cancer Res
22
2019
AKR1C3, AKR1C3 mRNA, ALL, ALL PDXs, B, B-ALL, B-ALL PDX, B-lineage ALL, OBI-3424, PDX, PDXs, PURPOSE, T, T-, T-ALL, T-ALL PDXs, T-ALL cell lines, acute lymphoblastic leukemia, aldo-keto reductase family 1 member C3, castrate-resistant prostate cancer, hepatocellular carcinoma, mice, mouse, nelarabine, patient, primary T-lineage ALL
Author NameAffiliation
Kathryn EvansChildren's Cancer Institute
Chelsea MayohChildren's Cancer Institute
Yuelong Guo
Komal S RathiDivision of Oncology and Center for Childhood Cancer Research, Department of Biomedical and Health Informatics and Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Komal S RathiDivision of Oncology and Center for Childhood Cancer Research, Department of Biomedical and Health Informatics and Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Kathryn G RobertsSt. Jude Children's Research Hospital
Charles G MullighanSt. Jude Children's Research Hospital
Malcolm A Smith
Malcolm A Smith
Richard B LockChildren's Cancer Institute
  • 1 - 10

Datasets

Release 1.2